Litcius/Paper detail

Variants of Concern responsible for SARS-CoV-2 vaccine breakthrough infections from India

Urvashi B. Singh, Mercy Rophina, Rama Chaudhry, Vigneshwar Senthivel, Kiran Bala, Rahul C. Bhoyar, Bani Jolly, Nayer Jamshed, Mohamed Imran, Ritu Gupta, Praveen Aggarwal, Mohit Kumar Divakar, Subrata Sinha, Arvinden V.R., Anjali Bajaj, Afra Shamnath, Abhinav Jain, COVID CBNAAT CORE GROUP, Vinod Scaria, Sridhar Sivasubbu, Randeep Guleria

202112 citationsDOIOpen Access PDF

Abstract

Emerging reports of SARS-CoV-2 breakthrough infections entail methodical genomic surveillance for determining efficacy of vaccines. This study elaborates genomic analysis of isolates from breakthrough infections following vaccination with AZD1222/Covishield and BBV152/Covaxin.Variants of concern B.1.617.2 and B.1.1.7 responsible for cases surge in April-May 2021 in Delhi, were the predominant lineages among breakthrough infections.

Topics & Concepts

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)Vaccination2019-20 coronavirus outbreakMedicineBiologyOutbreakInfectious disease (medical specialty)DiseaseInternal medicineSARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsVaccine Coverage and Hesitancy
Variants of Concern responsible for SARS-CoV-2 vaccine breakthrough infections from India | Litcius